Kane Biotech Inc KNBIF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KNBIF is a good fit for your portfolio.
News
-
Kane Biotech to Host Investor Webinar
-
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
-
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
-
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
-
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
-
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
-
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
-
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
Trading Information
- Previous Close Price
- $0.11
- Day Range
- $0.09–0.09
- 52-Week Range
- $0.04–0.12
- Bid/Ask
- $0.09 / $0.12
- Market Cap
- $11.84 Mil
- Volume/Avg
- 84,000 / 25,873
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 103.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.kanebiotech.com
Valuation
|
Metric
|
KNBIF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 103.48 |
Price/Cash Flow | — |
Price/Earnings
KNBIF
Financial Strength
|
Metric
|
KNBIF
|
|---|---|
Quick Ratio | 0.08 |
Current Ratio | 0.34 |
Interest Coverage | −2.76 |
Quick Ratio
KNBIF
Profitability
|
Metric
|
KNBIF
|
|---|---|
Return on Assets (Normalized) | −69.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −687.62% |
Return on Assets
KNBIF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xcztnqbvy | Mdqk | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dsdtbzy | Ttgsk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wkzynnmv | Kgwcjj | $98.1 Bil | |
MRNA
| Moderna Inc | Jffqdjnj | Tll | $39.1 Bil | |
ARGX
| argenx SE ADR | Rlmgzqgv | Tnx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Zjhdpgtc | Czfvm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yrntlxf | Rfssdq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hnvclxn | Ymqkll | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dkmnvqqhjr | Dpcjzq | $12.5 Bil | |
INCY
| Incyte Corp | Jbtrjyzgt | Lylrxm | $11.9 Bil |